Key Takeaways Novo Nordisk stock rose on Tuesday after the Financial Times reported that an activist investor is building a ...

Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a ...

Hedge fund aims to influence CEO appointment as drugmaker battles share price slump and competition from Eli Lilly.

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The European Medicines Agency has indicated that Novo Nordisk's drugs, Ozempic and Wegovy, may rarely cause a serious eye ...

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

By triggering weight loss using the likes of Ozempic, people can expect various possible changes to their appearance ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...